Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(50%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph early_phase_1
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(2)

Detailed Status

Recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 21 (33.3%)

Trials by Status

withdrawn125%
recruiting250%
terminated125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

NCT06961084
recruitingphase_1

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358
withdrawn

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

NCT00373711
terminatedearly_phase_1

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

NCT00725946

Clinical Trials (4)

Showing 4 of 4 trials
NCT06961084Phase 2

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Recruiting
NCT03647358Phase 1

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Recruiting
NCT00373711

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Withdrawn
NCT00725946Early Phase 1

Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4